Satellos Bioscience Inc. (TSX:MSCL)

Canada flag Canada · Delayed Price · Currency is CAD
0.6200
+0.0200 (3.33%)
Sep 2, 2025, 3:59 PM EDT
3.33%
Market Cap105.78M
Revenue (ttm)n/a
Net Income (ttm)-31.09M
Shares Out176.31M
EPS (ttm)-0.22
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume267,987
Average Volume122,446
Open0.6000
Previous Close0.6000
Day's Range0.6000 - 0.6600
52-Week Range0.4500 - 1.3200
Beta0.66
RSI52.73
Earnings DateAug 12, 2025

About Satellos Bioscience

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British C... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 17
Stock Exchange Toronto Stock Exchange
Ticker Symbol MSCL
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.